Prothena stock trades at EUR 7.54 with USD 445 million market value

Published on 10/20/2026 at 12:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Prothena's Q2 revenue reached USD 1.01 million versus USD 0.42 million consensus. Prothena stock costs EUR 7.54 on October 20, 2026.

Quarterly revenue and ownership signals

William Scully reported purchases of 110,000 shares on October 13 and October 14, 2026.
Second-quarter revenue reached USD 1.01 million versus USD 0.42 million consensus on August 6, 2026.
Prothena stock traded at EUR 7.54 at 12:50 p.m. CEST at Lang & Schwarz on October 20, 2026.

PRTA, IE00B91XRN20, Illustration mit AI erstellt.

Prothena (ISIN IE00B91XRN20) was trading at EUR 7.54 at Lang & Schwarz on October 20, 2026, while its market capitalization stood at USD 445.0 million on October 16, 2026. The latest company filing reported that Chief Development Officer Chad Swanson resigned effective October 9, 2026, to join a strategic partner in a leadership role over a partnered program, according to the SEC.

What does the cash profile show?

Prothena's financial picture remains tied to licensing income and partner milestones. A market analysis published on October 19, 2026, said the company held USD 288.0 million in cash at the end of June and had no debt, while management guided to USD 18.0 million to USD 23.0 million of net cash use for 2026. The same analysis identified a USD 50.0 million milestone from Novo Nordisk as support for that outlook, while a possible USD 55.0 million Bristol Myers Squibb milestone was not included in the guidance.

The operating comparison is sharp. Prothena reported USD 1.01 million of second-quarter revenue on August 6, 2026, versus USD 0.42 million expected by analysts, while adjusted earnings per share were a loss of USD 0.32 against a projected loss of USD 0.39, according to The Cerbat Gem.

Three dated operating markers

On May 8, 2026, first-quarter revenue reached USD 51.1 million, driven mainly by USD 50.05 million of license and intellectual-property revenue. On August 6, 2026, second-quarter revenue was USD 1.01 million and the net loss narrowed to USD 18.6 million. On October 13 and October 14, 2026, ten-percent owner William Scully bought 100,000 shares and 10,000 shares at weighted average prices of USD 8.3548 and USD 8.4569, respectively, according to StockTitan.

Price and investor perspective

The stock's valuation reflects a development-stage company whose cash runway depends partly on future partner payments. Analysts tracked by MarketBeat held an average 12-month price target of USD 24.57 across eight firms on October 13, 2026, with ratings ranging from sell to strong buy, according to MarketBeat. The wide range of views leaves milestone timing and cash usage as the central variables for the investment case.

Prothena was trading at EUR 7.54 at Lang & Schwarz on October 20, 2026 at 12:50 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Prothena stock.